Missing periods in replicate designs: save the data? [RSABE / ABEL]

posted by Astea – Russia, 2019-10-20 14:46 (505 d 17:51 ago) – Posting: # 20709
Views: 5,955

Dear smart people!

I've got two questions on this topic, that could be logically combined into the one philosophical: should we try to keep as much data as possible for the analysis?

1). How would you advice to deal with subjects, who have only one (2,3..) points over LLOQ in one of the periods? According to EMA it is possible to exclude subjects with AUC of reference product less than 5% of geometric mean AUC. Should we exclude all the data of such a subject or can we remain data from other periods?
Example: acetylcalycic acid (ASA) in enteric-coated form has a wide-range Tmax in about 2 to 7 hours with extremely rapid conversion to salycic acid. So PK profiles look like "zero-zero-vertical line-zero-zero"... For catching it one has to plan a great number of sample points and use appropriate stabilization procedure. Even in these case there could be the uppermentioned problems.

2). What was the real reason for FDA to develop an algorithm for NTIDs with only complete data? As Helmut mentioned in the post, theoretically it is possible to use all the data even with incomplete data. Why then FDA just throw data of subjects with incomplete data to the bin? Is not it unethical? (I can't understand this point)

"Being in minority, even a minority of one, did not make you mad"

Complete thread:

 Admin contact
21,372 posts in 4,463 threads, 1,496 registered users;
online 7 (0 registered, 7 guests [including 3 identified bots]).
Forum time: Tuesday 07:38 CET (Europe/Vienna)

We learn more by looking for the answer to a question and not finding it
than we do from learning the answer itself.    Lloyd Alexander

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz